Volume 5, Issue 1 pp. 65-80
Progress In Liver Transplantation
Free Access

Management of hepatic metastases

Michael A. Choti

Corresponding Author

Michael A. Choti

Departments of Surgery and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD

Address reprint requests to Michael A. Choti, MD, Department of Surgery, Halsted 614, The Johns Hopkins Hospital, 600 North Wolfe St, Baltimore, MD 21287-4685Search for more papers by this author
Gregory B. Bulkley

Gregory B. Bulkley

Departments of Surgery and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD

Search for more papers by this author
First published: 30 December 2003
Citations: 59

Abstract

Although the liver is the most common site of metastatic disease from a variety of tumor types, isolated hepatic metastases most commonly occur from colorectal cancer and, less frequently, from neuroendocrine tumors, gastrointestinal sarcoma, ocular melanoma, and others. Complete evaluation of the extent of metastatic disease, both intrahepatically and extrahepatically, is important before considering treatment options. Based on a preponderance of uncontrolled studies for hepatic metastatic colorectal carcinoma, surgical resection offers the only potential for cure of selected patients with completely resected disease, with 5-year survival rates of 25% to 46%. Systemic and hepatic arterial infusion chemotherapy may be useful treatment options in patients with unresectable disease and possibly as an adjuvant treatment after liver resection. Other techniques of local tumor ablation, including cryotherapy and radiofrequency ablation, although promising, remain unproved. Management of hepatic metastases from neuroendocrine tumors and other noncolorectal primary tumors should be individualized based on the patient's clinical course, extent of disease, and symptoms.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.